1283 related articles for article (PubMed ID: 28463396)
1. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Kim C; Kim EK; Jung H; Chon HJ; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim SH; Kim HS
BMC Cancer; 2016 Jul; 16():434. PubMed ID: 27393385
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
8. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.
Knösel T; Altendorf-Hofmann A; Lindner L; Issels R; Hermeking H; Schuebbe G; Gibis S; Siemens H; Kampmann E; Kirchner T
J Clin Pathol; 2014 Jul; 67(7):592-8. PubMed ID: 24747207
[TBL] [Abstract][Full Text] [Related]
9. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
12. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
15. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
16. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
17. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
Pazzaglia L; Novello C; Conti A; Pollino S; Picci P; Benassi MS
Cell Oncol (Dordr); 2017 Feb; 40(1):77-88. PubMed ID: 27900663
[TBL] [Abstract][Full Text] [Related]
18. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
20. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.
Weitz J; Antonescu CR; Brennan MF
J Clin Oncol; 2003 Jul; 21(14):2719-25. PubMed ID: 12860950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]